Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
Incyte Corp (NASDAQ: INCY) closed the day trading at $95.16 down -1.59% from the previous closing price of $96.7. In other words, the price has decreased by -$1.59 from its previous closing price. On the day, 2.42 million shares were traded. INCY stock price reached its highest trading level at $97.98 during the session, while it also had its lowest trading level at $94.66.
Ratios:
For a better understanding of INCY, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 6.38 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 15.61. For the most recent quarter (mrq), Quick Ratio is recorded 3.13 and its Current Ratio is at 3.20. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
On November 03, 2025, Guggenheim Upgraded its rating to Buy which previously was Neutral but kept the price unchanged to $125.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 02 ’25 when Stein Steven H sold 20,105 shares for $102.51 per share. The transaction valued at 2,060,964 led to the insider holds 63,129 shares of the business.
Stein Steven H sold 2,559 shares of INCY for $263,475 on Dec 01 ’25. The EVP & Chief Medical Officer now owns 100,327 shares after completing the transaction at $102.96 per share. On Dec 02 ’25, another insider, STEVEN STEIN, who serves as the Officer of the company, bought 20,105 shares for $102.51 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, INCY now has a Market Capitalization of 18682068992 and an Enterprise Value of 16095852544. As of this moment, Incyte’s Price-to-Earnings (P/E) ratio for their current fiscal year is 15.96, and their Forward P/E ratio for the next fiscal year is 12.23. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.12. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.88 while its Price-to-Book (P/B) ratio in mrq is 4.01. Its current Enterprise Value per Revenue stands at 3.344 whereas that against EBITDA is 12.154.
Stock Price History:
The Beta on a monthly basis for INCY is 0.82, which has changed by 0.3339771 over the last 52 weeks, in comparison to a change of 0.12529528 over the same period for the S&P500. Over the past 52 weeks, INCY has reached a high of $109.28, while it has fallen to a 52-week low of $53.56. The 50-Day Moving Average of the stock is -0.83%, while the 200-Day Moving Average is calculated to be 23.90%.
Shares Statistics:
Over the past 3-months, INCY traded about 2.18M shares per day on average, while over the past 10 days, INCY traded about 2158090 shares per day. A total of 196.13M shares are outstanding, with a floating share count of 194.23M. Insiders hold about 1.07% of the company’s shares, while institutions hold 103.65% stake in the company. Shares short for INCY as of 1763078400 were 9495529 with a Short Ratio of 4.36, compared to 1760486400 on 9364129. Therefore, it implies a Short% of Shares Outstanding of 9495529 and a Short% of Float of 6.819999999999999.
Earnings Estimates
Incyte Corp (INCY) is presently subject to a detailed evaluation by 16.0 analysts, each offering their unique perspectives on its market standing.The consensus estimate for the next quarter is $1.61, with high estimates of $1.9 and low estimates of $1.33.
Analysts are recommending an EPS of between $7.16 and $6.53 for the fiscal current year, implying an average EPS of $6.83. EPS for the following year is $7.67, with 21.0 analysts recommending between $9.33 and $5.38.
Revenue Estimates
18 analysts predict $1.35B in revenue for. The current quarter. It ranges from a high estimate of $1.43B to a low estimate of $1.3B. As of. The current estimate, Incyte Corp’s year-ago sales were $1.18BFor the next quarter, 18 analysts are estimating revenue of $1.25B. There is a high estimate of $1.36B for the next quarter, whereas the lowest estimate is $1.18B.
A total of 21 analysts have provided revenue estimates for INCY’s current fiscal year. The highest revenue estimate was $5.06B, while the lowest revenue estimate was $4.92B, resulting in an average revenue estimate of $4.98B. In the same quarter a year ago, actual revenue was $4.24BBased on 20 analysts’ estimates, the company’s revenue will be $5.52B in the next fiscal year. The high estimate is $5.82B and the low estimate is $5.13B.
